CEOs have been offering up cuts to manufacturing operations as one antidote to sick balance sheets during the most recent round of earnings updates and Merck is among those whittling away.
A report, citing La Presse , says Merck is cutting a quarter of its workforce at a plant in Pointe Claire, Canada.
Merck ($MRK) is saying "so long" to Whitehouse Station, NJ. The drugmaker says it will move its global headquarters to nearby Summit, NJ, after 20 years there. The Summit site already houses 1,800 people working in several different Merck groups, and moving the HQ there will save space and money.
Authorities in Brazil have seized counterfeit versions of two Schering-Plough drugs that are popular among bodybuilders.
It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.
Merck says that vorapaxar , its troubled blood thinner once considered the jewel in Schering-Plough's crown when the pharma giant bought it for $41 billion, hit its primary efficacy endpoint in a
Merck has stumbled into one of the hidden traps of megamergers. The Department of Justice is probing the marketing of three drugs inherited from Schering-Plough, Merck disclosed to the SEC in a
Chalk up another victory for sales reps in their fight for overtime pay. A U.S. judge has decided that Schering-Plough sales people don't qualify for the administrative exemption under U.S. labor
This is what you call taking away with one hand while giving with the other. Merck says it's planning to invest €29 million ($41.8 million) at its plant in Cork, Ireland, and create 70 jobs
The U.S. Court of Appeals in Philadelphia has upheld an IRS ruling against Schering Plough, which leaves Merck with a $473 million IRS bill. The case stemmed from an interest rate swap with two of